The Prevalance of HMPV After COVID-19 PandemicNCT06309212
Assessing the Impact of COVID-19 on HMPV Incidence and Severity Among Adults
An observational study of The Prevalance of HMPV After COVID-19 Pandemic and The Importance of Accurate Diagnosis for HPMV, run by Acibadem University at 1 site in Turkey (Türkiye).
Trial summary
Human metapneumovirus (HMPV) is primarily recognized as a childhood pathogen, but its impact on adults remains largely underestimated. This study investigates the prevalence, clinical characteristics, and post-COVID-19 trends of HMPV infection among adults in Istanbul, Turkey. Read more about this study
- Who is it for?
- Ages 18 to 100 years
- Conditions the study is for
- The Prevalance of HMPV After COVID-19 Pandemic, The Importance of Accurate Diagnosis for HPMV
- What is being tested?
- Observation
- How many people
- 2,197 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 15 Dec 2023to 30 Jan 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 100 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: This retrospective study examined adults with acute respiratory tract infections in Istanbul, Turkey. Patients admitted between 2016-2020 (pre-COVID) and 2021-2023 (post-COVID) underwent multiplex PCR testing for various respiratory viruses, with a focus on human metapneumovirus. The study aimed to assess the prevalence of HMPV infection in adults and its potential change after the COVID-19 pandemic.
Who may be able to join
- Adults >18 years
- Patients with acute respiratory tract infection symptoms
- Patients who underwent multiplex PCR testing for respiratory viruses
Who cannot join
- Patients for whom no respiratory viral panel test was conducted
Trial locations and contacts
1 site in 1 country.
About this study
Human metapneumovirus (HMPV) is primarily recognized as a childhood pathogen, but its impact on adults remains largely underestimated. This study investigates the prevalence, clinical characteristics, and post-COVID-19 trends of HMPV infection among adults in Istanbul, Turkey.
Read the detailed description
Human metapneumovirus (HMPV) is primarily recognized as a childhood pathogen, but its impact on adults remains largely underestimated. This study investigates the prevalence, clinical characteristics, and post-COVID-19 trends of HMPV infection among adults in Istanbul, Turkey.
- Conditions
- The Prevalance of HMPV After COVID-19 Pandemic, The Importance of Accurate Diagnosis for HPMV
- Being tested
- Observation
- Keywords
- Adults, Human metapneumovirus, Post-COVID-19 era, Prevalence, Underestimated Virus
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ObservationOther
Analyse of data from adults with respiratory tract infections who were tested for various respiratory viruses using a multiplex PCR assay
| Study group | Role | What they receive |
|---|---|---|
| Pre-COVID period | January 2016 to January 2020 Receives: Other: Observation | |
| Post-COVID period | January 2021 to September 2023 Receives: Other: Observation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Prevalence of HMPV infection in adults pre- and post-COVID-19 pandemic
Analyse of data from adults with respiratory tract infections who were tested for various respiratory viruses using a multiplex PCR assay
Measured: Between 2016-2020 (pre-COVID) and 2021-2023 (post-COVID)
Secondary outcomes (1)
Comparison of HMPV with other respiratory viruses in adults
Analyse of data from adults with respiratory tract infections who were tested for various respiratory viruses using a multiplex PCR assay
Measured: Between 2016-2020 (pre-COVID) and 2021-2023 (post-COVID)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Mar 2024
- Study start15 Dec 2023
- Primary completion30 Dec 2023
- Study completion30 Jan 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for The Prevalance of HMPV After COVID-19 PandemicStudies of the same condition, open and under way.
- More trials run by Acibadem UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 2,197 participants (actual)
Sponsor and investigators
- Lead sponsor
- Acibadem University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06309212
- Sponsor's protocol ID
- 2023-20/687
- Status last verified
- Mar 2024
- First submitted
- 12 Mar 2024
- Last updated
- 13 Mar 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Niederman MS, Torres A. Respiratory infections. Eur Respir Rev. 2022 Oct 19;31(166):220150. doi: 10.1183/16000617.0150-2022. Print 2022 Dec 31.
PubMed 36261160Haas LE, Thijsen SF, van Elden L, Heemstra KA. Human metapneumovirus in adults. Viruses. 2013 Jan 8;5(1):87-110. doi: 10.3390/v5010087.
PubMed 23299785Boivin G, De Serres G, Hamelin ME, Cote S, Argouin M, Tremblay G, Maranda-Aubut R, Sauvageau C, Ouakki M, Boulianne N, Couture C. An outbreak of severe respiratory tract infection due to human metapneumovirus in a long-term care facility. Clin Infect Dis. 2007 May 1;44(9):1152-8. doi: 10.1086/513204. Epub 2007 Mar 28.
PubMed 17407031Chow EJ, Uyeki TM, Chu HY. The effects of the COVID-19 pandemic on community respiratory virus activity. Nat Rev Microbiol. 2023 Mar;21(3):195-210. doi: 10.1038/s41579-022-00807-9. Epub 2022 Oct 17.
PubMed 36253478Pearson V. Case studies. Baton Rouge puts community first. Trustee. 1995 May;48(5):24-6. No abstract available.
PubMed 10142898
Study at a glance
From the registry record, last updated by the sponsor on 13 Mar 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Assessing the Impact of COVID-19 on HMPV Incidence and Severity Among Adults
- ClinicalTrials.gov ID
- NCT06309212
- Acronym / sponsor ID
- 2023-20/687
- Conditions
- The Prevalance of HMPV After COVID-19 Pandemic, The Importance of Accurate Diagnosis for HPMV
- Keywords
- Adults, Human metapneumovirus, Post-COVID-19 era, Prevalence, Underestimated Virus
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 2,197 participants (actual)
- Lead sponsor
- Acibadem UniversityUniversity, hospital or other
- Study start
- 15 Dec 2023 (actual)
- Primary completion
- 30 Dec 2023 (actual)
- Study completion
- 30 Jan 2024 (actual)
- First posted
- 13 Mar 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Human metapneumovirus (HMPV) is primarily recognized as a childhood pathogen, but its impact on adults remains largely underestimated. This study investigates the prevalence, clinical characteristics, and post-COVID-19 trends of HMPV infection among adults in Istanbul, Turkey.
Detailed description
Human metapneumovirus (HMPV) is primarily recognized as a childhood pathogen, but its impact on adults remains largely underestimated. This study investigates the prevalence, clinical characteristics, and post-COVID-19 trends of HMPV infection among adults in Istanbul, Turkey.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Pre-COVID period | – | Other: ObservationJanuary 2016 to January 2020 |
| Post-COVID period | – | Other: ObservationJanuary 2021 to September 2023 |
Who may qualify
- Ages
- 18 to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- This retrospective study examined adults with acute respiratory tract infections in Istanbul, Turkey. Patients admitted between 2016-2020 (pre-COVID) and 2021-2023 (post-COVID) underwent multiplex PCR testing for various respiratory viruses, with a focus on human metapneumovirus. The study aimed to assess the prevalence of HMPV infection in adults and its potential change after the COVID-19 pandemic.
Key inclusion criteria (3 listed)
- Adults >18 years
- Patients with acute respiratory tract infection symptoms
- Patients who underwent multiplex PCR testing for respiratory viruses
Key exclusion criteria (1 listed)
- Patients for whom no respiratory viral panel test was conducted
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ObservationAnalyse of data from adults with respiratory tract infections who were tested for various respiratory viruses using a multiplex PCR assay | Other | Post-COVID period, Pre-COVID period |
Primary outcome
Prevalence of HMPV infection in adults pre- and post-COVID-19 pandemic
Time frame: Between 2016-2020 (pre-COVID) and 2021-2023 (post-COVID)
Analyse of data from adults with respiratory tract infections who were tested for various respiratory viruses using a multiplex PCR assay
1 secondary outcome
Comparison of HMPV with other respiratory viruses in adults
Time frame: Between 2016-2020 (pre-COVID) and 2021-2023 (post-COVID)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Mar 2024.
- Background: PubMed 36261160Niederman MS, Torres A. Respiratory infections. Eur Respir Rev. 2022 Oct 19;31(166):220150. doi: 10.1183/16000617.0150-2022. Print 2022 Dec 31.
- Background: PubMed 23299785Haas LE, Thijsen SF, van Elden L, Heemstra KA. Human metapneumovirus in adults. Viruses. 2013 Jan 8;5(1):87-110. doi: 10.3390/v5010087.
- Background: PubMed 17407031Boivin G, De Serres G, Hamelin ME, Cote S, Argouin M, Tremblay G, Maranda-Aubut R, Sauvageau C, Ouakki M, Boulianne N, Couture C. An outbreak of severe respiratory tract infection due to human metapneumovirus in a long-term care facility. Clin Infect Dis. 2007 May 1;44(9):1152-8. doi: 10.1086/513204. Epub 2007 Mar 28.
- Background: PubMed 36253478Chow EJ, Uyeki TM, Chu HY. The effects of the COVID-19 pandemic on community respiratory virus activity. Nat Rev Microbiol. 2023 Mar;21(3):195-210. doi: 10.1038/s41579-022-00807-9. Epub 2022 Oct 17.
- Background: PubMed 10142898Pearson V. Case studies. Baton Rouge puts community first. Trustee. 1995 May;48(5):24-6. No abstract available.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of The Prevalance of HMPV After COVID-19 Pandemic and The Importance of Accurate Diagnosis for HPMV, run by Acibadem University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Mar 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Prevalence of HMPV infection in adults pre- and post-COVID-19 pandemic (time frame: Between 2016-2020 (pre-COVID) and 2021-2023 (post-COVID)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06309212, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Mar 2024.